Ultragenyx Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option to Purchase Additional Shares

News | 02. 05. 2014

Ultragenyx Pharmaceutical

NOVATO, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the closing of its initial public offering of 6,624,423 shares of common stock at an initial public offering price of $21.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 864,054 additional shares of common stock. All of the shares of common stock were offered by Ultragenyx. The company’s common stock is listed on The NASDAQ Global Select Market under the ticker symbol “RARE.” Ultragenyx estimates net proceeds from the offering to be approximately $126.4 million, after deducting underwriting discounts and commissions and estimated offering expenses.